Skip to main content
. Author manuscript; available in PMC: 2017 Aug 23.
Published in final edited form as: Gynecol Oncol. 2015 Mar 11;137(2):229–238. doi: 10.1016/j.ygyno.2015.03.002

Fig. 2. Standardization of the flow cytometry assay to measure iCTCs.

Fig. 2

(A). Analytical performance of the CTC flow cytometry assay for iCTCs using the experimental spiking model. (B). Analytical performance of the CTC flow cytometry assay for Epis using the experimental spiking model. (C). Stability of iCTCs in blood stored over time. Blood samples were stored at 4°C for period of time indicated. (D). An example of detection of iCTCs in blood of a normal donor and an EOC patient using the standardized assay. Numbers of iCTCs were measured in 1-mL of blood. In the first two panels, G1 and G2 gatings are illustrated by the curved lines in the lower right corners. The last panel (G1+G2) is a plot of the gated cells with TP positive on the X axis and CAM positive on the Y axis. (E) An example of detection of iCTCs and Epis in blood of an EOC patient one day prior to and two weeks post to treatment with taxol / carboplatin using the standardized assay. Numbers of iCTCs and Epis were measured in 1-mL of blood. (F) High detection sensitivity and specificity of iCTCs in normal, benign and patients within a stage. Error bars indicate SEM; horizontal lines within boxes are median; dots show outliers. (G). Detection of Epis in normal, benign and patients within a stage. Error bars indicate SEM; horizontal lines within boxes are median; dots show outliers.